109 related articles for article (PubMed ID: 38833768)
1. Target engagement of an anti-MT1-MMP antibody for triple-negative breast cancer PET imaging and beta therapy.
Magro N; Oteo M; Romero E; Ibáñez-Moragues M; Lujan VM; Martínez L; Vela O; López-Melero ME; Arroyo AG; Garaulet G; Martínez-Torrecuadrada JL; Mulero F; Morcillo MA
Nucl Med Biol; 2024 May; 136-137():108930. PubMed ID: 38833768
[TBL] [Abstract][Full Text] [Related]
2. MT1-MMP as a PET Imaging Biomarker for Pancreas Cancer Management.
Morcillo MÁ; García de Lucas Á; Oteo M; Romero E; Magro N; Ibáñez M; Martínez A; Garaulet G; Arroyo AG; López-Casas PP; Hidalgo M; Mulero F; Martínez-Torrecuadrada J
Contrast Media Mol Imaging; 2018; 2018():8382148. PubMed ID: 30224904
[TBL] [Abstract][Full Text] [Related]
3. Targeted beta therapy of prostate cancer with
Yeh MC; Tse BWC; Fletcher NL; Houston ZH; Lund M; Volpert M; Stewart C; Sokolowski KA; Jeet V; Thurecht KJ; Campbell DH; Walsh BJ; Nelson CC; Russell PJ
EJNMMI Res; 2020 May; 10(1):46. PubMed ID: 32382920
[TBL] [Abstract][Full Text] [Related]
4. Targeting MT1-MMP as an ImmunoPET-Based Strategy for Imaging Gliomas.
de Lucas AG; Schuhmacher AJ; Oteo M; Romero E; Cámara JA; de Martino A; Arroyo AG; Morcillo MÁ; Squatrito M; Martinez-Torrecuadrada JL; Mulero F
PLoS One; 2016; 11(7):e0158634. PubMed ID: 27462980
[TBL] [Abstract][Full Text] [Related]
5. Theranostic role of
Yang Q; Chen Z; Qiu Y; Huang W; Wang T; Song L; Sun X; Li C; Xu X; Kang L
Eur J Nucl Med Mol Imaging; 2024 Apr; 51(5):1246-1260. PubMed ID: 38135849
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of the theranostic potential of
Wu Y; Li T; Zhang X; Jing H; Li F; Huo L
EJNMMI Radiopharm Chem; 2024 Jan; 9(1):5. PubMed ID: 38194043
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, and preclinical evaluation of a novel bifunctional macrocyclic chelator for theranostics of cancers.
Xu J; Cai F; Luo Z; Fan W; Dai J; Cui J; Li S; Geng C; Zheng Q; Wang Z; Tang X
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2618-2633. PubMed ID: 35347438
[TBL] [Abstract][Full Text] [Related]
8. Dose predictions for [
Ku A; Kondo M; Cai Z; Meens J; Li MR; Ailles L; Reilly RM
EJNMMI Radiopharm Chem; 2021 Aug; 6(1):25. PubMed ID: 34383182
[TBL] [Abstract][Full Text] [Related]
9.
Poty S; Mandleywala K; O'Neill E; Knight JC; Cornelissen B; Lewis JS
Theranostics; 2020; 10(13):5802-5814. PubMed ID: 32483420
[No Abstract] [Full Text] [Related]
10. Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.
Perk LR; Stigter-van Walsum M; Visser GW; Kloet RW; Vosjan MJ; Leemans CR; Giaccone G; Albano R; Comoglio PM; van Dongen GA
Eur J Nucl Med Mol Imaging; 2008 Oct; 35(10):1857-67. PubMed ID: 18491091
[TBL] [Abstract][Full Text] [Related]
11. Radiolabelling and preclinical characterisation of [
Cao Z; Wichmann CW; Burvenich IJG; Osellame LD; Guo N; Rigopoulos A; O'Keefe GJ; Scott FE; Lorensuhewa N; Lynch KP; Scott AM
Eur J Nucl Med Mol Imaging; 2024 May; ():. PubMed ID: 38730087
[TBL] [Abstract][Full Text] [Related]
12.
Giesen D; Hooge MNL; Nijland M; Heyerdahl H; Dahle J; de Vries EGE; Pool M
Sci Rep; 2022 Apr; 12(1):6286. PubMed ID: 35428777
[TBL] [Abstract][Full Text] [Related]
13. ImmunoPET Imaging Identifies the Optimal Timepoint for Combination Therapy in Xenograft Models of Triple-Negative Breast Cancer.
Li Z; Belitzky E; Blaha O; Cavaliere A; Katz SR; Aboian M; Melegari L; Rajabimoghadam K; Kurpiewski S; Zhu X; Marquez-Nostra B
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900378
[TBL] [Abstract][Full Text] [Related]
14. Visualising dual downregulation of insulin-like growth factor receptor-1 and vascular endothelial growth factor-A by heat shock protein 90 inhibition effect in triple negative breast cancer.
Terwisscha van Scheltinga AG; Berghuis P; Nienhuis HH; Timmer-Bosscha H; Pot L; Gaykema SB; Lub-de Hooge MN; Kosterink JG; de Vries EG; Schröder CP
Eur J Cancer; 2014 Sep; 50(14):2508-16. PubMed ID: 25027745
[TBL] [Abstract][Full Text] [Related]
15.
Privé BM; Derks YHW; Rosar F; Franssen GM; Peters SMB; Khreish F; Bartholomä M; Maus S; Gotthardt M; Laverman P; Konijnenberg MW; Ezziddin S; Nagarajah J; Heskamp S
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):2064-2076. PubMed ID: 34932154
[TBL] [Abstract][Full Text] [Related]
16. Development of [
Cavaliere A; Sun S; Lee S; Bodner J; Li Z; Huang Y; Moores SL; Marquez-Nostra B
Eur J Nucl Med Mol Imaging; 2021 Feb; 48(2):383-394. PubMed ID: 32770372
[TBL] [Abstract][Full Text] [Related]
17. PET imaging of DNA damage using (89)Zr-labelled anti-γH2AX-TAT immunoconjugates.
Knight JC; Topping C; Mosley M; Kersemans V; Falzone N; Fernández-Varea JM; Cornelissen B
Eur J Nucl Med Mol Imaging; 2015 Oct; 42(11):1707-1717. PubMed ID: 26031435
[TBL] [Abstract][Full Text] [Related]
18. Panitumumab-DOTA-
Facca VJ; Cai Z; Gopal NEK; Reilly RM
Mol Pharm; 2022 Oct; 19(10):3652-3663. PubMed ID: 35926098
[TBL] [Abstract][Full Text] [Related]
19. An antibody-radionuclide conjugate targets fibroblast activation protein for cancer therapy.
Xu M; Chen J; Zhang P; Cai J; Song H; Li Z; Liu Z
Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3214-3224. PubMed ID: 37318538
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Theranostic Efficacy of
Chen Z; Yang Q; Song L; Qiu Y; Wang T; Wu S; Huang W; Sun X; Wang A; Kang L
Mol Pharm; 2024 May; 21(5):2544-2554. PubMed ID: 38588328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
